Breakthrough invasive fungal diseases in acute myeloid leukemia patients receiving mould active triazole primary prophylaxis after intensive chemotherapy: An Italian consensus agreement on definitions and management.
acute myeloid leukemia
antifungal prophylaxis
breakthrough fungal infections
triazoles
Journal
Medical mycology
ISSN: 1460-2709
Titre abrégé: Med Mycol
Pays: England
ID NLM: 9815835
Informations de publication
Date de publication:
01 Apr 2019
01 Apr 2019
Historique:
received:
05
07
2018
accepted:
27
09
2018
revised:
03
09
2018
entrez:
1
3
2019
pubmed:
1
3
2019
medline:
26
3
2019
Statut:
ppublish
Résumé
In the attempt to establish definitions and provide shared approaches to breakthrough invasive fungal diseases (br-IFD) in acute myeloid leukemia (AML) patients submitted to intensive chemotherapy and receiving triazoles as mould active primary antifungal prophylaxis (MA-PAP), literature on br-IFD in AML patients receiving triazoles MA-PAP was reviewed and a Consensus Development Conference Project was convened. The following four candidate key-questions were generated and formed the set of questions of the present document: "definition of br-IFD," "diagnostic strategy during MA-PAP to detect br-IFD," "possible causes of MA-PAP failure," "management of br-IFD."
Identifiants
pubmed: 30816979
pii: 5366909
doi: 10.1093/mmy/myy091
doi:
Substances chimiques
Antifungal Agents
0
Triazoles
0
Types de publication
Consensus Development Conference
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
S127-S137Informations de copyright
© The Author(s) 2019. Published by Oxford University Press on behalf of The International Society for Human and Animal Mycology.